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Introduction
Induced pluripotent stem cells (iPSCs), derived by transduc-
tion of somatic cells with OCT4, SOX2, KLF4, and c-MYC are 
defined as pluripotent in view of their ability to self-renew and 
differentiate into cell types representative of three embryonic 
germ layers (Takahashi et al., 2007; Park and Daley, 2009); 
however, several studies have shown considerable variation in 
their differentiation potential (Narsinh et al., 2011; Tobin and 
Kim, 2012). The mechanistic basis of this variation is poorly 
understood, but several hypotheses to account for these dif-
ferences have been proposed, such as incomplete epigenetic 
reprogramming (Ma et al., 2014), microRNA expression (Vi-
taloni et al., 2014), donor cell type (Kim et al., 2010), repro-
gramming factor selection (Buganim et al., 2014), differential 
activity of endogenous TGFβ signaling pathways (Zhou et al., 
2010; Pauklin and Vallier, 2013), and genetic variation be-
tween individual donors of the somatic cells used to generate 
iPSCs (Rouhani et al., 2014).
Human embryonic stem cell (hESC) lines vary in their 
propensity for differentiation (Osafune et al., 2008), but grow-
ing evidence suggests that even greater variability may be pres-
ent in human iPSCs (hiPSCs; Narsinh et al., 2011; Buganim 
et al., 2014; Ma et al., 2014), even though the genetic back-
ground of hiPSCs is likely to be more variable given their 
greater availability compared with hESC lines. Detailed com-
parisons of the ability of both hESC and hiPSC to generate 
specific types of somatic cells indicate that despite using 
identical transcriptional networks to generate cells such as 
those of the neuroepithelium, some hiPSC lines respond to 
such developmental programs with significantly reduced 
efficiency (Hu et al., 2010).
Parameters such as methylome analysis, expression of 
transcript regulators, and analyses of aneuploidy cannot be 
used to distinguish high- and low-quality hiPSC lines (Bu-
ganim et al., 2014). γH2A.X deposition patterns may distin-
guish the differentiation potential of hiPSCs (Wu et al., 2014); 
however, it would be helpful to have a rapid assay to assess the 
differentiation potential of hiPSCs. In this study, we identified 
CHC HD2, whose expression is often low or absent in hiPSCs 
when compared with hESCs, which is an efficient correlate of 
the potential of such hiPSCs to give rise to neuroectodermal 
lineages on differentiation.
Human induced pluripotent stem cell (hiPSC) utility is limited by variations in the ability of these cells to undergo lin-
eage-specific differentiation. We have undertaken a transcriptional comparison of human embryonic stem cell (hESC) 
lines and hiPSC lines and have shown that hiPSCs are inferior in their ability to undergo neuroectodermal differentiation. 
Among the differentially expressed candidates between hESCs and hiPSCs, we identified a mitochondrial protein, 
CHC HD2, whose expression seems to correlate with neuroectodermal differentiation potential of pluripotent stem cells. 
We provide evidence that hiPSC variability with respect to CHC HD2 expression and differentiation potential is caused 
by clonal variation during the reprogramming process and that CHC HD2 primes neuroectodermal differentiation of 
hESCs and hiPSCs by binding and sequestering SMAD4 to the mitochondria, resulting in suppression of the activity of 
the TGFβ signaling pathway. Using CHC HD2 as a marker for assessing and comparing the hiPSC clonal and/or line 
differentiation potential provides a tool for large scale differentiation and hiPSC banking studies.
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Results
Identification of differentially expressed 
transcripts between hESCs and hiPSCs
Six independently derived pluripotent stem cells lines were 
used, including two human embryonic stem cell lines (H9 and 
H1; WiCell Inc.) and four hiPSC lines generated using the 
lentiviral, nonintegrating Sendai virus and episomal vectors 
(NHDF-iPSC(L), NHDF-iPSC(S), 19-9-7T, and 19–9-11T; 
Table 1 and Fig. 1 A). The lentiviral- and Sendai-derived hiPSC 
lines were generated and characterized in our laboratory (Jiang 
et al., 2014; Chichagova et al., 2016) and fulfilled all pluripo-
tency criteria, whereas the episomal-derived lines (19-9-7T and 
19-9-11T) were purchased from WiCell Inc. (Yu et al., 2009). 
These pluripotent stem cells, cultured under identical feeder- 
free conditions, were differentiated into neural stem cells 
(NSCs) as outlined in Materials and methods. During plurip-
otent culture, all hESC and hiPSC lines demonstrated sim-
ilar expression of the key pluripotency markers NAN OG and 
TRA-1-60 (Fig. 1 B) in addition to the maintenance of plurip-
otent stem cell morphology (Fig. 1 A). We subjected all hESC 
and hiPSC lines to neuroectodermal differentiation using an 
embryoid body (EB)–based differentiation method (Fig.  1 C) 
and observed that all hiPSC lines showed a significant reduction 
in their differentiation ability as indicated by a reduction in the 
number of PAX6-positive cells (Fig. 1 D) and reduced SOX1 
expression when compared with hESCs (Fig. 1 E), corroborat-
ing previously published data (Hu et al., 2010).
The possibility of a hiPSC-specific defect leading to this 
observation prompted us to perform transcriptomic analysis of 
the pluripotent stem cell lines used in this work. Total RNA 
was extracted from undifferentiated hiPSCs and hESCs and 
also from NSCs obtained using the monolayer differentiation 
protocol (Fig. S1, A–D; this protocol was selected because it 
generates homogenous populations of NSCs) and hybridized to 
the Agilent SurePrint G3 Human Gene Expression 8 × 60K v2 
as described in Materials and methods. We used a cutoff fold 
change of >1.5 and P < 0.05 to identify differentially expressed 
genes between hESCs and hiPSCs. 4.2% of transcripts dis-
played decreased expression in hESCs compared with hiPSCs, 
and 3.9% showed decreased expression in hiPSCs compared 
with hESCs (Fig. 2, A and B; Fig. S2 A; and Table S2). Gene 
Ontology analysis (Genespring software) suggested that the 
majority of genes differentially expressed between hESCs and 
hiPSCs were likely to be involved in the synthesis and assembly 
of components of the extracellular matrix, regulation of tran-
scription, metabolic processes, and embryonic morphogenesis 
(Fig. 2 C and Table S3).
Transcriptomic data obtained from NSCs generated from 
all pluripotent stem cell lines (Fig. S1 and Fig. S2, B and C) 
was analyzed similarly. We found that 3.1% of transcripts were 
significantly increased and 3.4% of transcripts were signifi-
cantly decreased in NSCs derived from hiPSCs when compared 
with NSCs derived from hESCs (Table S4). Venn diagram 
analysis identified 436 common transcripts whose expression 
significantly differed between hESCs and hiPSCs at both the 
pluripotent and the NSC stages (Fig. 2 D and Table S5). Several 
of those highly changed transcripts between hESCs and hiPSCs 
(DPP6, FAM15A5, TCE RG1L, and CTSF) were identified in 
other recent studies (Ruiz et al., 2012; Huang et al., 2013), and 
their expression differences in hESCs and hiPSCs were con-
firmed by quantitative RT-PCR analysis (Fig. S2, D–G). How-
ever, one of the significantly changed transcripts identified in 
our study is CHC HD2, which was previously shown to be ex-
pressed in hiPSC-derived neuronal cells in a time-dependent 
manner (Shimojima et al., 2015). Quantitative RT-PCR anal-
ysis of CHC HD2 expression in all hESC and hiPSC lines at 
the pluripotent and NSC stages (Fig. 3 A) confirmed the array 
data and indicated that hESC lines express significantly higher 
levels of this gene compared with the four hiPSC lines included 
in this study, and this persists in the NSCs obtained from those 
lines. These findings were further confirmed at the protein level 
by Western immunoblotting (Fig.  3  B). The coding sequence 
of CHC HD2 is highly conserved between Homo sapiens, Mus 
musculus, and Rattus norvegicus (Fig. S2 H); therefore, the pos-
sibility that this gene plays a significant and hitherto unknown 
role in maintenance of pluripotency and differentiation into 
neuroectodermal cell types was worthy of further investigation.
We investigated CHC HD2 localization by immunofluo-
rescence in hESC/hiPSC and NSCs derived therefrom in com-
bination with MitoTracker red and mitochondrial transcription 
factor A (mtTFA; TFAM) to investigate if CHC HD2 expression 
does indeed localize to mitochondria as suggested (Aras et al., 
2015; Fig.  3  C). This indicated that not all hESCs expressed 
CHC HD2 (Fig.  3  C); however, in cells that did, its localiza-
tion corresponded perfectly with MitoTracker and mtTFA an-
tibody staining, suggesting a mitochondrial colocalization 
pattern (Fig. 3, C and D). The hiPSC line, 19-9-7T showed no 
CHC HD2 expression, corroborating the quantitative RT-PCR 
and Western immunoblotting data (Fig. 3, A–C). Similarly, all 
NSCs derived from hESCs (H9) expressed CHC HD2 at the 
mitochondria (Fig.  3, C and D), whereas a complete lack of 
CHC HD2 expression was observed in NSCs derived from the 
19–7-7T hiPSC line (Fig. 3, C and D).
CHC HD2 and its likely involvement in 
mitochondrial metabolism, apoptosis,  
and cell migration
Recent publications have attributed several functions to 
CHC HD2, including regulation of mitochondrial metabolism 
(Seo et al., 2010; Zubovych et al., 2010; Aras et al., 2015; Liu 
et al., 2015). Our group and others have provided evidence that 
Table 1. Schematic summary of hESCs and hiPSCs used in this study
Cell type Cell line Generated method Provider
hESCs H9 — WiCell
H1 — WiCell
hiPSCs NHDF-iPSC(L) Lentivirus Our laboratory
NHDF-iPSC(S) Sendai virus Our laboratory
19-9-7T Nonintegrating vector WiCell
19-9-11T Nonintegrating vector WiCell
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hESCs and hiPSCs rely on the glycolytic pathway and have an 
underdeveloped mitochondrial network and low mitochondrial 
activity (Armstrong et al., 2010; Prigione et al., 2010). Given the 
potential involvement of CHC HD2 in regulation of mitochon-
drial metabolism and its mitochondrial localization, as well as 
the differences in expression patterns between hESC and hiPSC 
lines, we went on to examine several parameters of mitochon-
drial function as shown in Fig. S3 (A–F). Very few significant 
differences in mitochondrial complex IV quantity and activity 
could be detected between hESCs and hiPSCs and the respec-
tive NSCs derived therefrom (Fig. S3, A and B), apart from a 
slight decrease in the rate of oxygen consumption observed 
in NSCs derived from hiPSCs (Fig. S3, C and D) and a corre-
sponding decrease in the relative levels of ATP (Fig. S3, E and 
F), very likely because of the absence (or, in some hiPSC lines, 
such as NHDF-iPSC(S), very low expression) of CHC HD2 in 
the mitochondria. Similarly, we could detect no significant dif-
ferences between hESCs and hiPSCs in the expression levels of 
genes encoded by the mitochondrial genome. The mitochondria 
of pluripotent stem cells are few and show an immature mor-
phology (Armstrong et al., 2010; Prigione et al., 2010); this 
was confirmed by transmission electron microscope (TEM) im-
aging of all pluripotent stem cell lines used in this work (Fig. 
S3 G). The same analysis also indicated greater numbers of 
mitochondria in NSCs derived from all pluripotent stem cell 
lines consistent with the increase in mitochondrial biogenesis 
during differentiation (Fig. S3 G). Moreover, the mitochondrial 
morphology NSCs shows more prominent cristae, indicating 
some degree of maturation but no obvious differences between 
hESC and hiPSC derived NSCs could be determined (Fig. S3 
G). Together, these data suggest that despite showing significant 
differences in expression of CHC HD2, hESCs and hiPSCs do 
not show notable differences in mitochondrial activity. Hence, 
it is unlikely that CHC HD2 function in pluripotent stem cells is 
linked to a possible function within mitochondria, which is con-
sistent with their glycolytic nature. However, some differences 
are observed in NSCs derived from pluripotent stem cells with 
different levels of CHC HD2 expression, which suggests that 
Figure 1. Variations in the ability of hiPSCs to undergo neuroectodermal differentiation. (A) Phase-contrast images of hESCs and hiPSCs used in this study. 
Bars, 100 µm. (B) Representative flow cytometric analysis indicating a high expression level of the pluripotency markers TRA1-60 and NAN OG. (C) All 
human pluripotent stem cells formed EBs in suspension culture. Bars, 100 µm. (D) Graph representation of flow cytometric analysis for PAX6 expression 
at day 8 of neural induction process. Data are shown as mean ± SEM (n = 3). **, P < 0.005. (E) Immunofluorescence with SOX1 antibody at day 15 of 
neural induction process (nuclei were labeled with blue-fluorescent DAPI). Bars, 100 µm.
o
n
 N
ovem
ber 3, 2016
D
ow
nloaded from
 
Published October 17, 2016
JCB • Volume 215 • NumBer 2 • 2016190
with the onset of differentiation, a mitochondrial CHC HD2- 
related function may become more prevalent.
Ectopic expression of CHC HD2 in NIH3T3 fibroblasts 
has been linked to increased motility after mechanical damage 
of cell monolayers (Seo et al., 2010). Accordingly, wound-heal-
ing studies in NSCs derived from all the hESCs and hiPSCs 
(Fig. S4 A) indicated reduced NSC migration capacity (Fig. 
S4 B) in hiPSC-derived NSCs compared with hESC-derived 
NSCs. Down-regulation of CHC HD2 by RNAi (Fig. S4, C 
and D) in hESC-derived NSCs resulted in reduced NSC migra-
tion capacity (Fig. S4 E). In contrast, transient up-regulation 
of CHC HD2 in NSCs derived from the NHDF-iPSC(L) hiPSC 
line (Fig. S4, F and G) resulted in increased migration capac-
ity (Fig. S4 H). Together, these data suggest that reduced CHC 
HD2 expression in hiPSCs and NSCs derived therefrom may 
impact cell migration, which could lead to differentiation- 
related impairments, as cell migration and differentiation are 
two highly coordinated events during early embryonic develop-
ment (Friedl and Gilmour, 2009).
Mitochondria-localized CHC HD2 protein can regulate Bax 
oligomerization and apoptosis by binding to mitochondrial 
Bcl-xL (Liu et al., 2015). In response to apoptotic stimuli, 
CHC HD2 expression decreases and loses its mitochondrial 
localization, which is accompanied by decreased Bcl-xL–
Bax interaction and increased Bax homo-oligomerization and 
Bax–Bak hetero-oligomerization, thus negatively regulating the 
apoptotic cascade upstream of Bax oligomerization. Accord-
ingly, our results indicate that there are no significant differ-
ences in the rate of cell death among all six pluripotent stem cell 
lines despite variable expression of CHC HD2 (Fig. S4 I). How-
ever, upon exposure to cisplatin, which can induce cell death in 
hESCs and hiPSCs, pluripotent stem cell lines (19-9-7T) lack-
ing CHC HD2 expression showed a higher rates of apoptosis 
(Fig. S4 J). Down-regulation of CHC HD2 in hESCs by RNAi 
(Fig. S4, K and L) enhanced cell death upon cisplatin exposure 
(Fig. S4 M), whereas transient overexpression of CHC HD2 in 
the hiPSC line 19-9-7T (which lacks CHC HD2 expression) 
reduced cisplatin-induced cell death (Fig. S4, N–P). Together, 
these data suggest that CHC HD2 can regulate stress-induced 
apoptosis in pluripotent stem cell lines.
CHC HD2 expression primes pluripotent 
stem cells to differentiate toward 
neuroectodermal lineages
Because NHDF-iPSC(L), NHDF-iPSC(S), 19-9-7T, and 19-9-
11T hiPSC lines underexpress CHC HD2 and show reduced ca-
pacity to differentiate to NSCs, we determined their potential to 
generate cells representative of the three embryonic germ layers 
during EB-mediated differentiation. This relied on quantitative 
RT-PCR analysis of genes specific to meso-endoderm and meso-
Figure 2. Transcriptional profiling demon-
strating differences between hiPSCs and hESCs 
and NSCs derived therefrom. (A) Unsuper-
vised hierarchical clustering of global gene 
expression data in hESCs and hiPSCs. (B) 
Global view of gene expression comparison 
between hESCs and hiPSCs. The array data 
were filtered using P < 0.05 and fold change 
>1.5.  (C) Gene Ontology analysis of genes 
with different expression levels in hESCs and 
hiPSCs. The Gene Ontology terms are noted 
on the y axis and the log10(p-value) on the x 
axis. (D) Venn diagram analysis visualizing 
the overlap between the genes differently ex-
pressed in hESCs versus hiPSCs as well as 
NSCs derived from both sources.
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derm (MIXL1 and T), endoderm (FOXA2 and GATA4), ectoderm 
(SOX1, SOX2, NES TIN, and PAX6) and trophectoderm (CDX2, 
EOM ES, and HAND1) and enabled us to assess whether inferior 
differentiation of hiPSC lines lacking CHC HD2 expression was 
related to a general differentiation defect or specific to the neuro-
ectodermal lineage only. The morphology of EBs generated from 
NHDF-iPSC(L), NHDF-iPSC(S), 19-9-7T, and 19-9-11T lines 
was similar (unpublished data), but significant differences were 
observed in the relative expression levels of embryonic germ 
layer markers. Expression of ectodermal markers is higher in 
EBs derived from hESC lines (Fig. 4 A) correlating with higher 
expression of CHC HD2 (Fig. 3, A and B). In contrast, hESC- 
derived EBs show a lower expression of all the other markers 
(with the exception of T only) typical of mesodermal, endodermal, 
and trophoectodermal differentiation (Fig. 4 A) when compared 
with hiPSC-derived EBs. Higher expression of endodermal and 
mesodermal markers during differentiation of hiPSC with very 
low or absent expression of CHC HD2 indicates that their differen-
tiation to other lineages is not affected, corroborating previously 
published data (Jiang et al., 2014). Together, these data suggest 
that lower expression of CHC HD2 in hiPSCs may be associated 
with a reduced differentiation capacity of pluripotent stem cell 
lines to neuroectodermal lineages, which is in turn compensated 
by differentiation to other embryonic and primitive lineages.
We investigated the impact of CHC HD2 expression 
levels on the pluripotent phenotype in more detail by stably 
Figure 3. CHC HD2 expression in human pluripotent stem cells and NSCs derived therefrom. (A) Quantitative RT-PCR results indicate that CHC HD2 expres-
sion is significantly lower in hiPSCs than in hESCs, and this difference is maintained in NSCs. Data are shown as mean ± SEM (n = 3). **, P < 0.005. 
(B) Western blot analysis of CHC HD2 in human pluripotent stem cells and NSCs derived therefrom. (C) Immunofluorescence with CHC HD2 antibody and 
MitoTracker red or CHC HD2 and mtTFA antibodies showing CHC HD2 expression in H9 and NSC-H9, but not in 19-9-7T or NSC-7T. Please note that 
CHC HD2 expression is only localized to the mitochondria of a subset of hESCs and all NSCS derived therefrom (nuclei were labeled with blue-fluorescent 
DAPI). Bars, 10 µm. (D) Schematic chart of colocalization coefficients between CHC HD2 and MitoTracker red or CHC HD2 and mtTFA in hiPSCs and NSCs 
derived therefrom. Data are shown as mean ± SEM (n ≥ 4).
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Figure 4. CHC HD2 and its impact on the spontaneous differentiation of human pluripotent stem cells. (A) Quantitative RT-PCR results with markers of 
neuroectoderm (PAX6, SOX1, SOX2, and NES TIN), mesoderm (MIXL1 and T), endoderm (FOXA2 and GATA4), and trophectoderm (CDX2, EMO ES, and 
HAND1) at day 6 of differentiation. Data are shown as mean ± SEM (n = 3). *, P < 0.05; **, P < 0.005. (B) Phase-contrast images of 19-9-7T cells 
stably transfected with vector or CHC HD2 construct. Bars, 200 µm. (C) Representative flow cytometric analysis indicating a high percentage of TRA1-60 
and NAN OG expression. (D) Quantitative RT-PCR analysis to assess the overexpression of CHC HD2 in CHC HD2 stable overexpression 19-9-7T. Data 
are shown as mean ± SEM (n = 3). ** P < 0.005. (E) Western blot analysis to assess the overexpression of CHC HD2 in CHC HD2 stable overexpression 
19-9-7T. (F) Double staining of CHC HD2 and MitoTracker red or CHC HD2 and mtTFA indicates that CHC HD2 expression is localized to the mitochondria 
in 19-9-7T-CHC HD2 cells (nuclei were labeled with blue-fluorescent DAPI). Bars, 10 µm. (G) Schematic chart of colocalization coefficient between CHC HD2 
and MitoTracker red or CHC HD2 and mtTFA. Data are shown as mean ± SEM (n ≥ 4). (H) Quantitative RT-PCR analysis indicating increased expression 
of neuroectodermal markers at the expense of other germ lineage markers upon stable overexpression of CHC HD2 in 19-9-7T. Data are shown as mean ± 
SEM (n = 3). **, P < 0.005. (I) Flow cytometric analysis at day 8 of neural induction indicating increased commitment to neuroectodermal lineages upon 
overexpression of CHC HD2 in 19-9-7T. Data are shown as mean ± SEM (n = 3). *, P < 0.05.
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transfecting a CHC HD2 expression construct into the hiPSC 
line with the lowest levels of CHC HD2 expression (19-9-7T; 
see Materials and methods for more details). This gave several 
morphologically similar hiPSC clones (Fig. 4, B and C) that ex-
pressed significantly more CHC HD2 (assessed by quantitative 
RT-PCR, Western blot, and immunofluorescence analysis) than 
control transfected cells (Fig.  4, D–G). Although the level of 
CHC HD2 expression in the overexpressing hiPSC clone (19-9-
7T–CHC HD2) was not as high as that seen in hESCs (Fig. 4 D), 
this was still able to increase the expression of neuroectodermal 
markers at the expense of markers delineating embryonic and 
primitive germ layers (Fig. 4 H) and to enhance differentiation 
to neuroectodermal lineages (Fig. 4 I).
To address the question of whether defined media condi-
tions could bypass the preferential lineage determination im-
posed by CHC HD2 expression, hESCs and hiPSCs with high 
and low levels of CHC HD2 expression were subjected to a 
monolayer differentiation protocol that gives rise to definitive 
endodermal progenitors (Rashid et al., 2010; Hannan et al., 
2013) characterized by the expression of SOX17 at day 3 as well 
as a defined EB-based differentiation that gives rise to primitive 
(CD34+CD43+) and definitive (CD34+CD43−) hematopoietic 
progenitors at day 6 of differentiation (Kennedy et al., 2012). 
Both of these defined differentiations indicated that the hiPSC 
lines without CHC HD2 expression show higher SOX17 expres-
sion and a higher percentage of hematopoietic progenitors upon 
endodermal and hematopoietic differentiation, respectively 
(Fig. S5, A and B). CHC HD2 overexpression reversed these 
trends in hiPSC lines with low endogenous CHC HD2 levels. 
Together with the lower propensity to differentiate toward neu-
roectodermal lineages (refer to Fig. 1, D and E), these data sug-
gest that expression of CHC HD2 primes pluripotent stem cell 
differentiation to neuroectodermal lineages at the expense of 
mesoendodermal and primitive lineages.
To confirm that our observations were not a laboratory- 
specific phenomenon, we analyzed CHC HD2 expression in a set 
of seven hiPSC lines shown to differentiate efficiently to neural 
lineages and 11 hiPSC lines that were classified either as type 
I defective (unable to differentiate efficiently to neural lineages 
and containing OCT4-positive undifferentiated cells in pretrans-
plantation samples) or type II defective (unable to differentiate 
efficiently to neural lineages, but not containing OCT4-positive 
cells in pretransplantation samples; Koyanagi-Aoi et al., 2013). 
Eight hESC lines deemed free of this neural differentiation 
inability from this study were also included in our analysis 
(Koyanagi-Aoi et al., 2013). As can be seen in Fig. 5 A, signif-
icant differences were found in CHC HD2 expression between 
hESC and hiPSC lines with good neural differentiation poten-
tial and defective hiPSCs that show inefficient neural differen-
tiation. These data suggest that our findings are applicable to 
hiPSC lines derived, characterized, and differentiated in other 
laboratories and are not a laboratory-specific phenomenon.
All four hiPSC lines included in this study generated with 
three different methods displayed lower CHC HD2 expression, 
indicating that this is unlikely to be related to the hiPSC deriva-
tion method (Fig. 3, A and B). We investigated the hypothesis 
that low CHC HD2 expression is caused by clonal variations 
associated with the reprogramming process. To investigate this 
further, we reprogrammed a human neonatal fibroblast line (Neo 
1 fibroblasts; Fig. 5 B) and two human adult dermal fibroblasts 
(AD2 and AD3; Fig. 5 B). To investigate if the CHC HD2 differ-
ential expression pattern was correlated with differential ability 
to undergo neuroectodermal differentiation, we selected two 
established hiPSC clones (Ad2 CL1 and Ad3 CL1; Fig. 5 C) 
derived from two different adult fibroblast samples. After con-
firming their pluripotent phenotype (Fig.  5  D) and CHC HD2 
expression in relation to our lowest-expressing hiPSC line (19-
9-7T; Fig. 5, E and F), we subjected them to the same differen-
tiation protocol used for the neural lineages shown in Fig. 1 D 
and observed that hiPSCs with higher levels of CHC HD2 ex-
pression differentiated to neuroectodermal lineages more ef-
ficiently (Fig. 5 G). Together, our data suggest that CHC HD2 
expression can vary in hiPSC clones; however, expression above 
a certain threshold seems to correlate with an enhanced ability to 
undergo neuroectodermal differentiation. Furthermore, differen-
tial expression of CHC HD2 within clones derived from the same 
fibroblast sample reinforces the concept that this is an intraclone 
variation issue and is not related to genetic heterogeneity of fi-
broblasts samples from which hiPSCs are derived.
Regulation of CHC HD2 expression during 
reprogramming
To address the question of how such intraclonal variability is 
generated with respect to CHC HD2 expression, we analyzed the 
expression of OCT4, SOX2, KLF4, and c-MYC in three hiPSC 
clones (AD3: CL7, CL8, and CL9) derived from one adult fi-
broblast sample (AD3; Fig.  6  A). We observed that higher 
CHC HD2 expression correlated with higher OCT4 and SOX2 
expression (Fig. 6, A and B, note AD3-CL8), suggesting that 
these two master pluripotency factors may regulate CHC HD2 
expression. Furthermore, we performed Sendai virus–based 
transduction of OCT4, SOX2, KLF4, and c-MYC in the same 
adult fibroblast sample (AD3) and monitored the expression of 
CHC HD2 3 d after transduction. Again, we observed increased 
CHC HD2 expression in samples transduced with OCT4 and 
SOX2 but no change in KLF4 and c-MYC transduced fibroblasts 
(Fig. 6 C). Bioinformatic screening found two OCT4 and two 
SOX2 binding sites in the 3-kb predicted CHC HD2 promoter 
region (Fig. 6 D). Chromatin immunoprecipitation (ChIP) assays 
using the H9 hESC line indicated binding of OCT4 to P1 and P2 
regions of CHC HD2 promoter (Fig. 6 E). SOX2 showed stronger 
binding to the P1 region of the CHC HD2 promoter and weaker 
binding to the P2 region (Fig. 6 E). Control experiments with 
KLF4 and c-MYC antibodies showed no binding in either of the 
two selected CHC HD2 promoter regions. Together, these data 
indicate that OCT4 and SOX2 bind to the CHC HD2 promoter 
region and regulate its expression. We also provide evidence to 
support the argument that higher OCT4 and SOX2 expression 
in selected hiPSC clones results in higher CHC HD2 expression, 
which further indicates intraclonal variation with respect to their 
differentiation to neuroectodermal lineages. The high expression 
of CHC HD2 in fibroblasts compared with clonal hiPSC lines sug-
gests that other factors in addition to OCT4 and SOX2 are likely 
to regulate CHC HD2 expression at the pluripotent stem cell stage 
and during their differentiation. This work is currently ongoing 
in our group with the aim of better understanding the role of 
this gene in hiPSC biology and cell lineages derived therefrom.
CHC HD2 influences the differentiation and 
survival of human pluripotent stem cells 
through the TGFβ signaling pathway
High TGFβ signaling activity has been linked to poor neuro-
ectodermal differentiation (Zhou et al., 2010; Morizane et al., 
2011; Pauklin and Vallier, 2013). Given the correlation between 
o
n
 N
ovem
ber 3, 2016
D
ow
nloaded from
 
Published October 17, 2016
JCB • Volume 215 • NumBer 2 • 2016194
lack of CHC HD2 expression and the lower ability to give rise to 
neuroectodermal derivatives described in this paper, we inves-
tigated possible interactions between CHC HD2 and the TGFβ 
signaling pathway. Previous studies have shown that CHC HD2 
and SIRT1 as well as SIRT1 and SMAD 4 (an essential pro-
tein involved in signal transduction of the TGFβ signaling path-
way) can interact with each other (Law et al., 2009; Chen et 
al., 2014). We performed coimmunoprecipitation experiments 
with CHC HD2 and SMAD4 antibodies in lysates of whole cells 
and nuclear and mitochondrial fractions. These experiments 
indicated that SMAD4 interacts with CHC HD2 in the mito-
chondria (Fig. 7 A). Given the interaction between CHC HD2 
and SMAD4, we went on to investigate SMAD4 expression 
using Western immunoblotting of nuclear and mitochondrial 
extracts of control and respective CHC HD2-overexpress-
ing hiPSC lines (19-9-7T) as well as control and respective 
knockdown CHC HD2 cell lines. This analysis indicated that 
SMAD4 is predominantly expressed in the nucleus; however, 
Figure 5. CHC HD2 expression correlates with the neural differentiation potential of hiPSC derived and characterized in our laboratory as well as others. 
(A) Large-scale transcriptional data from eight hESCs and 18 hiPSCs reported by Koyanagi-Aoi et al. (2013) to have different potentials to differentiate 
into neural lineages were analyzed for CHC HD2 expression. Data are shown as mean ± SEM (n = 3). (B) Relative CHC HD2 mRNA levels in H9, neonatal 
(Neo-1) fibroblast, adult (AD3) fibroblast, and reprogrammed hiPSC clones derived from them (Neo1-1# to 7# and AD3-1# to 9#). Data are shown as 
mean ± SEM (n = 3). (C) Phase contrast images of hiPSC lines Ad2 CL1 and Ad3 CL1. Bars, 100 µm. (D) Representative FACS analyses showing a high 
expression of TRA1-60 and NAN OG in Ad2 CL1 and Ad3 CL1. (E) Relative expression of CHC HD2 in 19-9-7T, Ad2 CL1, and Ad3 CL1. Data are shown 
as mean ± SEM (n = 3). **, P < 0.005. (F) Western blot analysis of CHC HD2 in 19-9-7T, Ad2 CL1, and Ad3 CL1 lines. (G) Representative FACS analysis 
at day 8 of neural induction showing variable proportion of PAX6-positive cells from hiPSCs. Data are shown as mean ± SEM (n = 3). **, P < 0.005.
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upon CHC HD2 overexpression, less SMAD4 is found in the 
nucleus and more in mitochondria. This is further corroborated 
by CHC HD2 down-regulation experiments, which indicate 
higher SMAD4 expression in the nucleus and lower expres-
sion in the mitochondria, suggesting a shuffling mechanism be-
tween the two (Fig. 7 B).
To further prove the interaction between CHC HD2 and 
TGFβ activity, the Cignal SMAD reporter, which contains tan-
dem repeats of the SMAD transcriptional response element, 
was transfected into HEK293 cells in which CHC HD2 was tran-
siently overexpressed or down-regulated by RNAi (Fig. 7 C). 
The specificity of this reporter was tested by adding a TGFβ 
inhibitor (SB 431542) to the culture media, which resulted in 
a significant down-regulation of reporter activity as expected. 
Down-regulation and overexpression of CHC HD2 in these cells 
caused a respective increase and decrease in the activity of the 
SMAD reporter (Fig. 7 C), suggesting an inverse link between 
CHC HD2 expression and TGFβ signaling activity. Accordingly, 
we also found that the expression of two key phosphorylated 
receptor-regulated SMADs (pSMAD2 and pSMAD3) was in-
creased in cell lines lacking CHC HD2 expression (19-9-7T) 
or human ESC lines where CHC HD2 expression was down- 
regulated by RNAi (Fig.  7, D and E). In contrast, overex-
pression of CHC HD2 in the 19-9-7T hiPSC line, which lacks 
endogenous CHC HD2 expression, resulted in a decrease in 
expression of the phosphorylated SMADs without notable 
changes in total SMAD2, SMAD3, or SMAD4 expression 
(Fig. 7, D and E), corroborating findings reported in Fig. 7 C 
via the TGFβ reporter. Furthermore, expression of five targets 
of the TGFβ signaling pathway (NOD AL, TGFβ1, ID1, LEF TY, 
and NAN OG) showed reciprocal correlation with CHC HD2 
expression (up-regulated in response to CHC HD2 down-regu-
lation and down-regulated when CHC HD2 was up-regulated; 
Fig. 7 F), strongly suggesting a direct link between CHC HD2 
expression and the TGFβ pathway activity.
To investigate if we could modulate the impact of 
CHC HD2 on human pluripotent stem cell differentiation via 
modulation of TGFβ pathway activity, we repeated the spon-
taneous differentiation experiment with hESCs in which 
CHC HD2 expression was down-regulated by RNAi in addi-
tion to down-regulation of both CHC HD2 and inhibition of 
the TGFβ signaling pathway. Although down-regulation of 
CHC HD2 suppressed differentiation to neuroectodermal lin-
eages and enhanced differentiation to trophoectodermal, en-
dodermal, and mesodermal lineages (Fig.  7  G), combined 
inhibition of CHC HD2 with TGFβ signaling pathway reversed 
these impacts (Fig. 7 G), suggesting that the TGFβ pathway acts 
downstream of CHC HD2. Similar results were obtained when 
TGFβ inhibition was applied during directed differentiation of 
human iPSC that lack CHC HD2 expression (Fig. 7 H), previ-
ously shown to be deficient at differentiating toward neuroecto-
dermal lineages (Fig. 1, D and E). Furthermore, the reduction 
Figure 6. Variable expression of CHC HD2 in hiPSC clones and regulation of its expression during the reprogramming process. (A) Relative CHC HD2, 
OCT4, SOX2, KLF4, and c-MYC mRNA levels in AD3-CL7#, AD3-CL8#, AD3-CL9#. Data are shown as mean ± SEM (n = 3). (B) Western blot analysis 
of CHC HD2 in AD3-CL7#, AD3-CL8#, and AD3-CL9#. (C) Relative CHC HD2 mRNA levels in AD3 fibroblasts and AD3 fibroblasts transduced with 
Sendai-EGFP, Sendai-OCT4, Sendai-SOX2, Sendai-KLF4, and Sendai-c-MYC for 3 d. Data are shown as mean ± SEM (n = 3). **, P < 0.005. (D) Sche-
matic presentation of CHC HD2 promoter showing the location of the putative OCT4 and SOX2 binding sites, as well as the location of primers used for 
ChIP. OCT4 and SOX2 binding sites are highlighted in blue and red. NS, nonspecific primers for region without potential OCT4, SOX2 binding sites; 
P1, P2 specific primers for OCT4, SOX2 potential binding sites. (E) ChIP assays demonstrating the capacity of OCT4 and SOX2 to bind to the CHC HD2 
upstream fragment in H9 cells.
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in cell survival caused by the application of cisplatin in hiPSC 
lines lacking CHC HD2 expression was rescued by inhibition 
of the TGFβ signaling pathway (Fig. S5 C), suggesting that the 
interaction between TGFβ signaling and CHC HD2 is important 
not only for the early differentiation of human pluripotent stem 
cells but also for their survival in culture.
Discussion
Through transcriptional comparison of two hESC and four 
hiPSC lines generated using three different methods, we have 
shown that hiPSCs are inferior in their ability to differentiate 
to neuroectodermal lineages, and we have identified a new 
Figure 7. CHC HD2 represses TGFβ signaling activity. (A) CHC HD2 interacts with SMAD4. CHC HD2 and SMAD4 were immunoprecipitated (IP) and an-
alyzed for the presence of SMAD4 and CHC HD2 by Western blot from the protein lysates of whole cells, as well as nuclear and mitochondrial fractions. 
(B) CHC HD2 regulates Smad4 intracellular localization. SMAD4 is predominantly expressed in the nucleus; however, upon CHC HD2 overexpression, less 
SMAD4 is found in the nucleus and more in mitochondria. Upon CHC HD2 knockdown, more SMAD4 is found in the nucleus and less in mitochondria. 
Nuclear and mitochondrial fractions were isolated from 19-9-7T overexpressed with vector (OE-Vector) or CHC HD2 (OE-CHC HD2) and H9 transfected 
with si-NS (KD-Control) or si-CHC HD2 (KD-CHC HD2). Histone H3 and VDCA1 were used as nuclear and mitochondrial markers, respectively. (C) SMADs 
transcriptional activity is repressed by CHC HD2. Cells were cotransfected with the reporter plasmid with the vector or CHC HD2 construct (left) or cotrans-
fected with the reporter plasmid with si-NS or si-CHC HD2 (right). Cells that were transfected with the reporter and incubated with 10 µM SB431542 were 
used as controls. Data are shown as mean ± SEM (n = 3). **, P < 0.005. (D) Western blot analysis of phosphorylated-SMAD2 (p-SMAD2), total-SMAD2, 
phosphorylated-SMAD3 (p-SMAD3), total-SMAD3, SMAD4, and CHC HD2 in the cells as indicated. (E) Relative protein expression levels in indicated cells. 
Data are shown as mean ± SEM (n = 3). *, P < 0.05; **, P < 0.005. (F) Quantitative RT-PCR results of TGFβ-related genes in the cells as indicated. Data are 
shown as mean ± SEM (n = 3). *, P < 0.05; **, P < 0.005. (G) Quantitative RT-PCR results of markers of neuroectoderm (PAX6), mesoderm (MIXL1), endo-
derm (GATA4), and trophectoderm (CDX2, HAND1) at day 6 of spontaneous differentiation of H9 cells transfected with si-NS or si-CHC HD2 or si-CHC HD2 
with TGFβ inhibitors. Data are shown as mean ± SEM (n = 3). *, P < 0.05; **, P < 0.005. (H) Graph representation of flow cytometric analysis for PAX6 
expression at day 8 of the monolayer differentiation process. Data are shown as mean ± SEM (n = 3). **, P < 0.005.
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marker, CHC HD2, whose expression differs significantly be-
tween hESC and hiPSC lines. Low CHC HD2 expression in 
hiPSC seems unrelated to the method of derivation (lentiviral, 
Sendai, or episomal vectors) and is not a laboratory-specific 
phenomenon because the data of other groups confirm our find-
ings (Koyanagi-Aoi et al., 2013). Our data suggest that differ-
ential expression of CHC HD2 is caused by clonal variations in 
the expression of OCT4 and SOX2, which bind to the CHC HD2 
promoter and activate its expression in a clone-dependent 
manner. CHC HD2 is able to interact directly with the TGFβ 
pathway by binding Smad4 in the mitochondria. This causes a 
reduction in nuclear location of SMAD4, which results in sup-
pression of TGFβ activity and enhanced differentiation toward 
neuroectodermal lineages.
To date, there is paucity of information about the func-
tions of CHC HD2 (in particular, its possible contribution to 
the maintenance of pluripotency), yet it is highly conserved 
among human, mouse, and rat, suggesting an important role 
for CHC HD2 (Aras et al., 2015). Most published studies 
suggest that CHC HD2 is a regulator of mitochondrial me-
tabolism active in both the mitochondria and the nucleus. In 
the former, it regulates the activity of cytochrome c oxidase, 
whereas in the nucleus, it stimulates transcription of a sub-
set of genes that includes COX4I2 (and itself under stress 
conditions). CHC HD2 knockdown results in reduced mito-
chondrial complex IV activity and increased reactive oxygen 
species production (Aras et al., 2013, 2015). Our studies in-
dicate that although CHC HD2 localizes to the mitochondria, 
nuclear localization is not observed even when mitochondrial 
entry of CHC HD2 is prevented by application of inhibitors 
such as Mito Block 6 (Aras et al., 2015) in both hiPSCs and 
NSCs derived therefrom (unpublished data). What CHC HD2 
does in the mitochondria is less clear. Although mutations 
in nonmammalian CHC HD2 homologues, such as HAR-1 in 
Caenorhabditis elegans, disrupt mitochondrial network for-
mation and impair ATP production (Zubovych et al., 2010), 
we might anticipate a similar response to the lower levels of 
CHC HD2 expression in hiPSCs, but despite differential ex-
pression of CHC HD2 between the hESC and hiPSC lines used 
in this study, we observed no significant differences in mi-
tochondrial complex IV quantity and activity or relative ATP 
levels and oxygen consumption rates (Fig. S3, A–F). This is 
not unexpected, because hESCs and hiPSCs have immature 
mitochondria and rely heavily upon glycolysis for ATP gener-
ation (Armstrong et al., 2010; Bukowiecki et al., 2014); how-
ever, differentiation of pluripotent stem cells into cell types 
with higher ATP demand is accompanied by an increase in mi-
tochondrial numbers and an increase in ATP synthesis by ox-
idative phosphorylation (Facucho-Oliveira et al., 2007; Yanes 
et al., 2010). In accordance with this, we found that NSCs 
derived from hiPSC lines (with lower CHC HD2 expression) 
showed a reduced oxygen respiration rate and reduced rela-
tive ATP levels, but again, this was modest when compared 
with hESC-derived NSCs (Fig. S3, A–F). Such NSCs have 
higher mitochondrial mass (Fig. S3 G) but lower complex IV 
activity (Fig. S3 A). The higher mitochondrial mass relative 
to the amount of complex IV protein may reflect the need for 
other mitochondrial functions. Neural progenitor cells tend to 
still rely on glycolysis (Gershon et al., 2013), because their 
normal niche in the brain is quite hypoxic, so there is little 
need for mitochondrial respiratory complexes. NSCs might 
need the larger numbers of mitochondria because they use a 
lot more fatty acid metabolism such as mitochondrial fatty 
acid β oxidation (Knobloch et al., 2013). A similar require-
ment for fatty acid oxidation might be common to many types 
of adult stem cells, particularly during quiescence (Ito et al., 
2012); however, we cannot be absolutely sure the same applies 
to our hiPSC-derived NSCs. It has already been shown that 
hESC-derived NSCs have a lower ATP demand and reduced 
mitochondrial activity when compared with hESCs (Birket et 
al., 2011), which indicates that the presence of a higher num-
ber of mitochondria does not guarantee a higher complex IV 
quantity and activity. Nevertheless, this prompted us to inves-
tigate mitochondrial parameters that could lead to reduced 
ATP synthesis, such as mitochondrial membrane potential, but 
we did not observe significant differences in membrane poten-
tial between hESCs and hiPSCs and NSCs derived therefrom, 
nor did we observe increased production of reactive oxygen 
species (a hallmark of defective oxidative phosphorylation) 
when hESCs were compared with hiPSCs or hESC-derived 
NSCs were compared with hiPSC-derived NSCs (unpublished 
data). In view of this, it is unlikely that subtle differences in 
mitochondrial respiration function observed between hESC- 
and hiPSC-derived NSCs are the cause of the impaired neuro-
ectodermal differentiation observed as consequence of lower 
CHC HD2 expression in hiPSCs.
The precise mechanism by which variable levels of 
CHC HD2 expression dictate the corresponding variability 
in neuroectodermal differentiation capacity prompted us to 
investigate the impact of this gene upon the TGFβ signaling 
pathway. High TGFβ activity negatively impacts the ability 
of hESCs and hiPSCs to differentiate toward neuroectoderm 
(Zhou et al., 2010; Morizane et al., 2011; Pauklin and Vallier, 
2013), and many defined differentiation protocols for this lin-
eage involve dual SMAD inhibition, which enables the plurip-
otent stem cells to progress with differentiation (Chambers et 
al., 2009; Zhou et al., 2010; Pauklin and Vallier, 2013). Inter-
estingly, we discovered that CHC HD2 interacts directly with 
SMAD4, a co-Smad, capable of subsequent binding to the 
receptor regulated Smads, resulting in a complex that enters 
the nucleus, where it acts as a transcription factor for various 
target genes of the TGFβ signaling pathway. Smad4 has been 
shown to translocate to mitochondria, where it associates with 
mitochondrial protein cytochrome c oxidase subunit II to reg-
ulate the apoptotic response (Pang et al., 2011). Furthermore, 
CHC HD2 also has been shown to bind and regulate cyto-
chrome c oxidase activity in 293 cells (Aras et al., 2015); nev-
ertheless, a direct interaction between CHC HD2 and SMAD4 
as reported herein has not been reported previously. As shown 
here, some hESC and hiPSC lines are able to undergo differ-
entiation to neuroectoderm without the additional need for 
TGFβ inhibition, suggesting different levels of activity for 
this pathway across hESC and hiPSC lines. This concurs with 
differential endogenous expression of CHC HD2 and the abil-
ity to give rise to neuroectoderm across human pluripotent 
stem cell lines as reported herein and leads us to hypothesize 
that hESC and hiPSC cell lines with endogenous CHC HD2 
expression are able to self-regulate TGFβ signaling activity 
via the CHC HD2–SMAD4 interaction. This is backed up by 
our experimental data, which indicate that in the presence of 
CHC HD2, SMAD4 nuclear expression is lower, whereas its 
mitochondrial expression is higher. Together, these data sug-
gest that CHC HD2 sequesters SMAD4 to the mitochondria 
via direct protein binding and makes it less available to enter 
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the nucleus to activate the TGFβ signaling targets. Accord-
ingly, we have shown that hiPSC lines with absent or reduced 
expression of CHC HD2 have higher expression of phosphor-
ylated receptor-regulated Smads, nuclear Smad4, and TGFβ 
signaling targets and higher TGFβ activity, whereas the op-
posite is true for pluripotent stem cell lines with endogenous 
CHC HD2 expression, strongly suggesting a direct inverse 
relationship between CHC HD2 and TGFβ pathway activ-
ity in pluripotent stem cells. This is reinforced by inhibition 
of TGFβ pathway activity, which is able to rescue the neu-
roectodermal differentiation ability of cell lines with absent 
CHC HD2 expression and their response to apoptotic stimuli, 
providing further evidence that CHC HD2 most likely controls 
the neuroectodermal differentiation of hESCs and hiPSCs via 
regulation of TGFβ pathway activity.
Although we report here a novel interaction between 
CHC HD2 and SMAD4, is still possible that CHC HD2 regu-
lates pluripotent stem cell differentiation through other inter-
acting factors. CHC HD2 has been suggested to interact with 
YBX1 (Wei et al., 2015), which has recently been shown to 
play a role in positively affecting the expression of Nanog 
and other pluripotency-related genes (Guo et al., 2016). Par-
ticularly, down-regulation of YBX1 results in high expression 
of mesoderm markers (Guo et al., 2016). In addition, YBX-1 
binds to the SOX2 promoter and down-regulates its expres-
sion in MCF7 and ZR751 (Jung et al., 2014). In addition, 
YBX-1 can interact physically and functionally with CTCF, 
which is a pluripotency factor in hESCs (Chernukhin et al., 
2000; Balakrishnan et al., 2012). Although the CHC HD2 and 
YBX1 interaction needs to be confirmed in human pluripo-
tent stem cells, these findings raise the tantalizing possibilities 
that CHC HD2 impacts differentiation and that differentiation 
could also be dependent on YBX1 or novel, yet-unidentified 
interacting proteins.
In conclusion, our study underlines the incomplete un-
derstanding of the mechanisms by which somatic cell–induced 
reprogramming affects the ability of hiPSCs to undergo neuro-
ectodermal differentiation. Although a few papers have reported 
differences in the ability of pluripotent stem cells to undergo 
directed differentiation to various lineages, this is a relatively 
unexplored territory and very important for comparing hiPSC 
lines and selecting the most appropriate hiPSC lines for fu-
ture cell banking and regenerative purposes (Hu et al., 2010; 
Zimmermann et al., 2012; Solomon et al., 2015). Multilineage 
differentiation (including differentiation to ectodermal cells) is 
generally accepted as an indicator of hiPSC line “quality,” but 
markers of such quality and methods to improve this charac-
teristic are incompletely met needs. Much progress has been 
made toward the establishment of “naive” or “ground state” 
pluripotency, but the data highlighted in this current study sug-
gest the involvement of the recently described gene CHC HD2 
in several molecular processes that contribute to induced plu-
ripotency and the ability of hiPSC clones to undergo neuroec-
todermal differentiation with similar efficiency to hESCs. In 
view of this, we propose that CHC HD2 expression is a valu-
able indicator of hiPSC quality that can be performed readily 
as a measure of how successful the expanded hiPSC clones are 
in their ability to undergo neuroectodermal differentiation. It 
is clear that future work needs to address the possibly multi-
ple mechanisms through which CHC HD2 may interact with 
other systems to contribute to the differentiation potential of 
pluripotent stem cells.
Materials and methods
hPSC culture
All hESC and hiPSC lines were maintained on plates coated with 
Matrigel (growth factor reduced; BD) with mTeSR1 (STE MCE LL 
Technologies) at 37°C, 5% CO2, and 21% O2 according to WiCell Inc. 
protocols. Cells were passaged every 4–5 d at ∼80% confluence by 
using 0.02% EDTA (Versene). Colonies containing clearly visible dif-
ferentiated cells were manually removed before further passaging.
NSCs culture
NSCs were maintained on flasks coated with poly-l-ornithine/laminin 
(Sigma-Aldrich) with N2B27 medium containing DMEM/F12, N2 
supplement (1:100, Invitrogen), B27 supplement (1:50, Invitrogen), 
100 mM nonessential amino acids (Invitrogen), 100 U/ml penicillin, 
and 100 mg/ml streptomycin (Invitrogen) plus 10 ng/ml FGF2 (R&D 
Systems) and 10 ng/ml EGF (R&D Systems). The cells were passaged 
every 4–6 d at ∼90% confluence by using Accutase. All NSCs used in 
this study were between passages 6 and 10.
EB-based neural differentiation from hESCs and hiPSCs
The procedure used for neural induction of hPSCs was based on a pre-
viously described protocol with a minor modification (Hu et al., 2010). 
In brief, on day 0, hPSCs were enzymatically detached by collagenase 
IV and dispase treatment and then dissociated into small clumps and 
cultured in suspension with mTeSR1 in a low-attachment plate for 
24 h. From day 1, the aggregates were transferred into differentiation 
medium (KO-DMEM; Invitrogen), 2  mM l-glutamine (Invitrogen), 
100  mM nonessential amino acids (Invitrogen), and 20% serum re-
placement (Invitrogen) for 6 d. The aggregates were then adhered to 
plates coated with Matrigel (growth factor reduced; BD) in neural in-
duction medium consisting of DMEF/F12, N2 supplement, and 2 µg/ml 
heparin as detailed previously (Hu et al., 2010).
Gene expression analysis
The SurePrint G3 Human Gene Expression 8 × 60K v2 Microarray kit 
from Agilent were used for the gene expression assay of each cell line 
with two biological replicates. RNA samples were prepared from by 
ReliaPrep RNA Cell Minprep System (Promega). Data were analyzed 
using Genespring software.
Accession numbers
Microarray data have been submitted to the Gene Expression Omnibus 
and are available under accession number GSE67325.
Flow cytometry analysis
Whole cultures (adherent cells or suspension aggregates) were dissoci-
ated by treatment with Accutase (Invitrogen) for 3 min and analyzed for 
expression of various neural and pluripotency markers by flow cytometric 
analysis, which was performed with a FAC SCaliber (BD). Data were ana-
lyzed with CellQuest Pro (BD) as described in the manufacturer's instruc-
tions. At least 10,000 events were analyzed in each replicate. Antibodies 
used for FACS were FITC-conjugated TRA-1-60 (1:200, FCM AB115F; 
EMD Millipore), NAN OG conjugated with Alexa Fluor 647 (D73G4, 
1:200; Cell Signaling Technology), PAX6 (PRB-278P, 1:100; Covance), 
NES TIN (MAB5326, 1:200; EMD Millipore), anti–rabbit IgG-FITC 
(Sigma-Aldrich), and anti–mouse IgG-FITC (Sigma-Aldrich).
RNA extraction, reverse transcription, and quantitative RT-PCR
Total RNA isolation was performed using the ReliaPrep RNA Cell Min-
prep System (Promega). RNA quality was evaluated using the Nano-
Drop 2000 spectrophotometer (Thermo Fisher Scientific), and reverse 
o
n
 N
ovem
ber 3, 2016
D
ow
nloaded from
 
Published October 17, 2016
CHC HD2 and hiPSC differentiation potential • Zhu et al. 199
transcription was performed using the GoScript Reverse Transcription 
System. Quantitative RT-PCR was performed using the QuantStudio 7 
Flex Real-Time PCR System (Thermo Fisher Scientific) and the GoTaq 
qPCR Master (Promega) according to the manufacturer’s instructions. 
Primer sequences used for quantitative RT-PCR are provided in Table S1.
Western blotting
30 µg protein from whole-cell extracts or cellular fraction extracts was 
used for Western blotting analysis. Antibodies used for Western blot-
ting were CHC HD2 (HPA027407, 1:200; Sigma-Aldrich) and GAP DH 
(G9545, 1:2,000; Sigma-Aldrich), SIRT1 (2493, 1:1,000; Cell Signal-
ing Technology), SMAD4 (9515, 1:1,000; Cell Signaling Technology), 
p-SMAD2 (3108, 1:1,000; Cell Signaling Technology), SMAD2 (5339, 
1:1,000; Cell Signaling Technology), p-SMAD3 (9520, 1:1,000; Cell 
Signaling Technology), SMAD3 (9523, 1:1,000; Cell Signaling Technol-
ogy), histone H3 (ab1791, 1:3,000; Abcam), VDAC1 (ab15895, 1:1,000; 
Abcam), and β-tubulin (T4026, 1:800; Sigma-Aldrich). Quantification 
of Western blotting results was performed using ImageJ software.
Immunofluorescence staining
In brief, cells were fixed in 4% PFA (Sigma-Aldrich) for 15 min, fol-
lowed by a 10-min permeabilization step (0.1% Triton X-100 in PBS 
for internal cell markers). The blocking step was performed by incuba-
tion in 2% BSA for 30 min. Cells were incubated with primary antibod-
ies at 4°C overnight and further incubated with secondary antibodies 
for 1 h. For MitoTracker dye staining, cells were cultured in the normal 
media with 150 nM MitoTracker red (Invitrogen) for 30 min before 
further fixation and immunostaining. Antibodies against the following 
proteins were used at the indicated dilutions: CHC HD2 (HPA027407, 
1:200; Sigma-Aldrich), SOX1 (4194S, 1:200; Cell Signaling Tech-
nology), NES TIN (MAB5326, 1:200; EMD Millipore), TUJ1 (MRB-
435P, 1:500; Covance), mtTFA (ab119684, 1:500; Abcam), anti–mouse 
IgG-FITC (1:800; Sigma-Aldrich), and anti–rabbit IgG-Cy3 (1:1,000; 
Jackson ImmunoResearch Laboratories, Inc.). Nuclei were labeled 
with DAPI (Thermo Fisher Scientific). Colocalization coefficient stud-
ies were performed using ImageJ software by calculating Manders’ 
colocalization coefficient, which describes the amount of colocalizing 
pixels of GFP using pixels generated by RFP.
Mitochondrial complex IV quantity and activity
Mitoprofile Human Complex IV Activity and Quantity from Mitosci-
ences (Invitrogen) was used according to the manufacturer’s instruc-
tions for the determination of complex IV activity and levels using 40 µg 
protein per well in at least two independent measurements in quadru-
plicate. A Multiskan Ascent 96 microplate instrument from Thermo 
Fisher Scientific was used for analysis.
Measurement of respiration rates using a Seahorse XFe-96 analyser
Respiration rates were measured on adherent cells using a Seahorse 
XFe-96 analyzer (Seahorse Bioscience) according to the manufactur-
er’s instructions. The assay plates were coated with Matrigel (growth 
factor reduced; BD). Cells were seeded at ∼36 h (for hPSCs) or 24 h 
(for NSCs) before measurement in their normal growth medium. hESCs 
and hiPSCs were seeded at 4 × 104 cells per well as single cells (with 
ROCK inhibitor for the first 6 h and then washed out twice by PBS), 
and NSCs were seeded as single cells totaling 5 × 104 cells per well. 
The assay was performed in bicarbonate-free DMEM (Sigma-Aldrich) 
with 15 mM glucose, 2 mM l-glutamine, and 0.5 mM sodium pyruvate; 
media was warmed to 37°C and the pH set to 7.4. Cells were washed 
twice and preincubated in the medium for 1  h before measurement. 
Oligomycin was used at 1.5 µM, FCCP was added in two injections of 
0.3 µM to 0.5 µM. Rotenone and antimycin A was added at 1 µM and 
2  µM. Oxygen consumption values were measured three times after 
each injection. After the assay, a standard protein assay was performed. 
The oxygen consumption rate was normalized to protein levels.
ATP measurement
ATP levels were measured using the CellTiter-Glo Luminescent Cell 
Viability Assay (Promega) according to the manufacturer’s instruc-
tions. In brief, 7 × 104 hPSCs (with 10  µM ROCK inhibitor for the 
first 6 h, and then washed out twice by PBS) or NSCs as single cells 
were seeded 18 h (for hPSCs) or 12 h (for NSCs) in their culture media 
before the measurement. Cells were then washed twice with warm PBS 
and incubated for 6 h in the measurement medium with 5 mM glucose 
plus 2 mM pyruvate, 5 mM glucose plus 2 mM pyruvate plus 1.5 µM 
oligomycin (glycolytic ATP generation), 5  mM 2-deoxy-d-glucose 
plus 2 mM pyruvate (oxidative ATP production), or 5 mM 2-deoxy-d- 
glucose plus 2 mM pyruvate plus 1.5 µM oligomycin. After incubation, 
cells were lysed, and lysates were incubated with the luciferin/lucifer-
ase reagents. Samples were measured using a NovoStar MBG Labtech 
microplate luminometer and the results referred to the cell viability by 
neutral red measurement (Sigma-Aldrich).
Wound-healing study
For wound-healing migration assays, NSCs were seeded onto poly- 
l-ornithine/laminin–coated six-well plates at a density of 7 × 105 
cells per well. 16  h after seeding, confluent cells were scratched by 
a fine pipette tip, washed with warmed PBS, and incubated in their 
normal growth media. After 0 and 24 h, pictures were taken under a 
phase microscope. Cell migration distance was determined by mea-
suring the wound width. The relative recovery rate was calculated as: 
[(initial wound width − wound width at the time of measurement)/ini-
tial wound width] × 100%.
Nondirected EB differentiation
In brief, on day 0, hPSCs were enzymatically detached by collage-
nase IV and dispase treatment, dissociated into small clumps, and 
cultured in suspension with mTeSR1 in a low-attachment plate for 
24 h. Aggregates (EBs) were then transferred into the differentiation 
media (KO-DMEM, 2 mM l-glutamine, 100 mM nonessential amino 
acids, and 20% knockout serum replacement; Invitrogen). The me-
dium was changed every 2 d.
Stable cell lines
The CHC HD2 full coding sequences were isolated from cDNA gen-
erated from the H9 hESC line using the following oligonucleotides: 
CHC HD2 forward, 5′-GTC GCT TAG CTC TTC GGT GG-3′; CHC HD2 
reverse, 5′-TAC AGA GTA GGG ACA CCC CC-3′. The full-length frag-
ment was ligated into the pCAG-IP vector. hiPSCs were transfected 
with control empty vector or CHC HD2 construct by Lipofectamine 
3000 (Invitrogen) following the manufacturer’s instructions. 2 d after 
transfection, stable clones were selected by using puromycin (0.5–1.0 
µg/ml) for 7 d.  Positive clones were expanded in mTeSR1 with 0.5 
µg/ml puromycin and labeled as 19-9-7T vector or 19-9-7T-CHC HD2. 
The expression level of CHC HD2 in stable cell lines was assessed by 
quantitative RT-PCR, Western blotting, and immunostaining.
Fibroblast reprogramming
Fibroblast cells were reprogrammed using the CytoTune-iPS 2.0 Sen-
dai Reprogramming kit (Invitrogen) according to the manufacturer’s 
instructions. In brief, fibroblast cells were seeded at 105 cells per well. 
24 h later, cells were then transfected with Sendai virus from the Cyto-
tune 1 kit (Thermo Fisher Scientific). 7 d after transfection, cells were 
dissociated into single cells by trypsinization (0.05% trypsin; Gibco) 
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and then plated onto Matrigel-coated plates with mTeSR1 media at 
a density of 2 × 104 ∼ 1 × 105 cells per well of a six-well plate. The 
media was changed every day until day 28, and pluripotent colonies 
were mechanically transferred to a four-well plate for further expan-
sion and characterization.
ChIP analysis
ChIP analysis was performed using the ChIP-IT Express Chromatin 
Immunoprecipitation kit (Active Motif) according to the manufactur-
er’s instructions. Five percent of the total genomic DNA from the nu-
clear extract was used as the input. The primers used for this procedure 
are provided in Table S1. The antibodies used for ChIP were OCT4 
(39811; Active Motif), SOX2 (39843; Active Motif), and rabbit IgG 
(AB-105-C; R&D Systems).
Monolayer neural differentiation
The monolayer protocol was modified from previous published pro-
tocols with minor modifications. In brief, we used a combination of 
three inhibitors (1  µM compound C; Sigma-Aldrich), together with 
500 ng/ml rmNoggin and 10 μM SB431542 (Sigma-Aldrich) to induce 
neural differentiation At day 14, the cells were picked as clumps, and 
plated onto a poly-l-ornithine/laminin–coated plate with N2 medium. 
When the polarized cells were visible, the cells were dissociated into 
single cells using Accutase and expanded in the N2B27 medium plus 
10 ng/ml basic FGF and 10 ng/ml EGF.
Neurosphere-forming assay
NSCs were dissociated to single cells using 0.05% trypsin and cul-
tured in suspension conditions. Neurosphere formation was observed 
from day 2 or day 3 in NSC culture media supplemented with basic 
FGF and EGF. When basic FGF and EGF were withdrawn, NSCs 
spontaneously differentiated into neuronal cells. Differentiated 
spheres were attached onto coverslips coated with Matrigel for immu-
nofluorescence staining.
Transmission electron microscopy
Cells were collected and fixed with 2.5% glutaraldehyde in 0.1  M 
phosphate buffer, pH 7.4, for 20 min at room temperature. After being 
rinsed for 10 min in the same buffer, cells were postfixed with 1% OsO4 
in 0.04 M phosphate buffer containing 0.14 M sucrose for 10 min at 
4°C. After dehydration with a standard ethanol series and infiltration 
with epoxy resin, cells were transferred to beam capsules for polymer-
ization in the oven. The capsules were separated from the polymerized 
resin with a razor blade, and embedded cells in hardened blocks were 
viewed with an optical microscope so that the appropriate area was 
chosen for ultrathin sectioning. Subsequently, ultrathin sections were 
obtained using an ultramicrotome (Sorvall MT-6000; DuPont) with a 
diamond knife. Heavy metal staining was done with 4% uranyl acetate 
and lead citrate, and the samples were examined through the electron 
microscope (H-7100; Hitachi) at 50 kV.
Cell transfection
hPSCs or NSCs were transfected with vector or CHC HD2 construct 
using Lipofectamine 3000 (Invitrogen) according to the manufacturer’s 
instructions. hPSCs or NSCs were transfected with si-NS or si-CHC 
HD2 using Lipofectamine RNAiMAX Transfection Reagent according 
to the manufacturer’s instructions.
Apoptosis assay
Apoptosis was quantified by Annexin V/FITC and phosphoinosit-
ide double staining by using the FITC Annexin V Apoptosis Detec-
tion kit I (BD, 556547) according to the manufacturer’s instructions. 
To induce apoptosis, cells were cultured in the normal medium with 
1 µg/ml cisplatin for 18 h.
Endoderm differentiation
The procedure for definitive endoderm differentiation of hPSCs was 
based on a previously described protocol (Rashid et al., 2010; Han-
nan et al., 2013). In brief, for initiation of definitive endoderm dif-
ferentiation, hPSCs were detached with EDTA (15575–020; Thermo 
Fisher Scientific), filtered through a 70-µm filter (352350; Corning) 
and seeded as small clumps in E8 media with 10 µM Y27632 (Y0503; 
Sigma-Aldrich) on gelatin-coated plates preincubated overnight with 
mouse embryonic fibroblast media. Differentiation was started 48  h 
later by changing media to day 1 media, consisting of CDM-PVA 
media + 100 ng/ml Activin A + 80 ng/ml FGF2 + 3 µM CHIR99021 
(CT99021; Stratech Scientific) + 10  µM LY (V1201; Promega) + 
10 ng/ml BMP4 (R&D Systems), followed by day 2 media, consisting 
of CDM-PVA media + 100 ng/ml Activin A + 80 ng/ml FGF2 + 10 µM 
LY + 10 ng/ml BMP4, and day 3 media, consisting of RPMI + 2% B27 
+ 100 ng/ml ActiviNa + 80 ng/ml FGF2.
Mesoderm differentiation
Before differentiation, cell lines were cultured on recombinant human 
vitronectin (A14700; Thermo Fisher Scientific) in StemPro hESC SFM 
medium (A1000701; Thermo Fisher Scientific). To generate uniform 
in shape and size EBs, hPSCs colonies were manually cut and scraped 
by using the StemPro EZPassage Stem Cell Tool (23181–010; Thermo 
Fisher Scientific). EBs were cultured in media supplemented with re-
combinant factors as previously described (Kennedy et al., 2012). All 
recombinant factors are human and purchased from PeproTech. Analysis 
of expression of KDR, CD34, and CD43 at the indicated time points was 
performed by flow cytometry using KDR-PE (560494; BD), CD34-APC 
(555824; BD), and CD43-FITC (MHCD4301; Thermo Fisher Scientific) 
antibodies. Analyses were performed by gating on single cells using 
forward scatter height versus area and followed by gating on live cells 
and lack of DAPI uptake. Stained cells were analyzed using LSR II (BD), 
and data analysis was performed using BD FAC SDiva software (BD).
Coimmunoprecipitation
For coimmunoprecipitation, cells were washed with cold PBS three 
times. Cell lysates were prepared in coimmunoprecipitation buffer 
(50 mM Tris-HCl, pH 7.5, 150 mM NaCl, 0.5% Nonidet P-40, 2 mM 
EDTA, 10% glycerol, 1 mM phenylmethylsulfonyl fluoride, and prote-
ase inhibitor cocktail; Roche), and protein concentration was measured 
using Bradford reagent (Bio-Rad Laboratories). Protein A/G PLUS 
agarose (sc-2003; Santa Cruz Biotechnology, Inc.) beads were washed 
three times with the coimmunoprecipitation buffer. 800 µg protein re-
covered from cell supernatants was precleared with 20 µl bead slurry 
and 2 µg rabbit IgG for at least 2 h on a rotor at 4°C. The beads were 
removed by centrifugation at 2,500 g for 5 min at 4°C.  Immunopre-
cipitation was performed by overnight incubation and rotation with 
the precleared cell lysate, 20 µl beads, 2 µg of rabbit anti-CHC HD2 
antibody (HPA027407; Sigma-Aldrich), rabbit anti-SMAD4 antibody 
(ab208804; Abcam), rabbit anti-SIRT1 antibody (2493; Cell Signaling 
Technology), or rabbit IgG. The beads with bound protein complexes 
were recovered by centrifugation at 2,500 g for 5 min and washed three 
times with coimmunoprecipitation buffer. The samples from immuno-
precipitation were examined using Western blot analysis.
Cellular subfractionation
Mitochondria were isolated from cells with the Mitochondrial Iso-
lation kit (89874; Thermo Fisher Scientific) according to the manu-
facturer’s protocol. The nuclear fraction was obtained by low-speed 
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centrifugation, and the mitochondrial fraction was obtained after high-
speed centrifugation of the nuclear supernatant.
Luciferase assays
Cells were seeded at a density of 105 per well into 24-well plates 
24 h before transfection. To examine the effect of CHC HD2 on the 
SMAD reporter, control vector, CHC HD2 expression plasmids, si-NS, 
or si-CHC HD2 was cotransfected with the reporter (Cignal SMAD 
Reporter, CCS-017L; QIA GEN) by Lipofectamine 3000 (Invitrogen) 
following the manufacturer’s instructions. Cell extracts were pre-
pared 48 h after transfection. Luciferase activity was evaluated with a 
Dual-Luciferase Assay System (Promega) according to the manufac-
turer’s recommendations.
Microscopy
Cell morphology was visualized using a microscope (Diaphot 300; 
Nikon) with the following objectives: 10× NA 0.25 and 20× NA 
0.40 at room temperature. Digital images were recorded using a 
digital camera (DXM1200; Nikon). Fluorescence sections were vi-
sualized using a microscope (Axio Imager Z1; Nikon) with the fol-
lowing objectives: 10× NA 0.25, 20× NA 0.40, and 40× NA 1.3 at 
room temperature. Digital images were recorded using a digital cam-
era (ApotomeCam; Nikon).
Statistical analysis
All values are shown as means ± SEM (n = 3). Statistical significance 
was assessed using Student's t test. For all statistical tests, the 0.05 
confidence level was considered statistically significant. In all figures, 
* denotes P < 0.05, ** denotes P < 0.005, and *** denotes P < 0.001 in 
an unpaired Student's t test.
Online supplemental material
Fig. S1 shows NSCs generated from hESCs and hiPSCs using a 
monolayer protocol. Fig. S2 shows the gene expression study in hESCs 
and hiPSCs and NSCs derived therefrom. Fig. S3 shows CHC HD2 
and its likely involvement in mitochondrial metabolism. Fig. S4 shows 
CHC HD2 and its likely involvement in cell migration and apoptosis. 
Fig. S5 shows the mesodermal and endodermal differentiation of 
human pluripotent stem cells; CHC HD2 protects hESC and hiPSC 
from apoptosis upon application of proapoptotic stimuli by regulating 
TGFβ. Table S1 lists the oligonucleotides used for quantitative RT-
PCR analysis and ChIP. Table S2 lists the genes showing differential 
expression between the hESCs and hiPSCs included in this study. Table 
S3 shows Gene Ontology analysis of transcripts showing significant 
differences in expression levels between the hESCs and hiPSCs 
included in this study. Table S4 lists the genes showing differential 
expression between hESC- and hiPSC-derived NSCs included in this 
study. Table S5 lists common transcripts whose expression significantly 
differed in hESCs and hiPSCs at both the pluripotent and NSC stages. 
Additional data are available in the JCB DataViewer at http ://dx .doi .org 
/10 .1083 /jcb .201601061 .dv.
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